Navigation Links
New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Date:9/19/2007

-1000 IU). The primary efficacy endpoint of the study was to demonstrate non- inferiority of the risedronate 150 mg monthly regimen to the risedronate 5 mg daily regimen as assessed by percent change from baseline in LS BMD at 12 months. The 24 month results will be reported at a later time. At 12 months, the mean LS BMD increases were 3.54% and 3.43% for the monthly and daily regimens, respectively. The most common adverse events for risedronate 5 mg and risedronate 150 mg, respectively, were upper abdominal pain (6.1% vs. 8.2%), influenza (4.2% vs. 8.9%) and constipation (7.3% vs. 5.8%).

The trial was sponsored by The Alliance for Better Bone Health.

About Actonel(R) (risedronate sodium tablets)

Actonel is approved for the prevention and treatment of osteoporosis in postmenopausal women. Actonel has been proven to reduce the incidence of vertebral fractures, and nonvertebral fractures at a composite endpoint of leg, hip, pelvis, clavicle, humerus and wrist. The following doses are approved: Actonel 5 mg daily, Actonel 35 mg once-a-week, and Actonel 75 mg two consecutive days per month.

In clinical trials, Actonel was generally well tolerated. Actonel is contraindicated in patients with hypocalcemia, known hypersensitivity to any component of this product, or inability to stand or sit upright for at least 30 minutes. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Actonel therapy. Actonel is not recommended for use in patients with severe renal impairment (creatinine clearance < 30 mL/min).

Bisphosphonates may cause upper gastrointestinal disorders such as dysphagia, esophagitis and esophageal or gastric ulcer. Patients should pay particular attention to the dosing instructions, as failure to take the drug according to instructions may compromise clinical benefits and may increase the risk of adverse events.

Among patients treated with bisphosphonates, there have be
'/>"/>

SOURCE The Alliance for Better Bone Health
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015 Research and ... of the "Market Assessment of Respiratory Diagnostics ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This ... imaging diagnostics market in the United ... . The service provides detailed analysis of the ...
(Date:5/21/2015)...  (MUSE Booth # 1510)What:Automating continuous vital sign ... invaluable in any hospital setting, but particularly for ... and mainstream in healthcare, the integration of data ... gaining traction in MEDITECH facilities.During MUSE 2015 (Medical ... Manager & Clinical Analyst at McLaren Huron Hospital, ...
(Date:5/21/2015)...  Heidrick & Struggles (Nasdaq: HSII ), the ... consulting and culture shaping worldwide, strengthens ... announcing the addition of Tim Dietlin to ... Dietlin has extensive life sciences and professional ... Medical and Commercial functions to increase productivity, drive transformational ...
Breaking Medicine Technology:United States and Europe Respiratory Diagnostics Market Assessment 2015 2Hospital Streamlines ICU Efficiency with Timely Data Integration 2Hospital Streamlines ICU Efficiency with Timely Data Integration 3Heidrick Increases Healthcare and Life Sciences Expertise 2
... Inc. announced today that it will present four,posters on ... which will be held at the San,Diego Convention Center ... 2007. , The following posters will be presented on ... San Diego Convention Center (Sails,Pavilion, Upper Level). , POSTER ...
... chemotherapy significantly,increases patients_ overall survival , BASEL, ... study published,yesterday in the Journal of Clinical ... to significantly improve,survival in patients with follicular ... is the most common type of,indolent lymphoma, ...
Cached Medicine Technology:Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007,American Psychiatric Association Annual Meeting 2Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 2Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 3Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 4
(Date:5/23/2015)... IL (PRWEB) May 23, 2015 A live ... medical equipment from hospitals, surgery centers and other medical facilities ... be sold including endoscopy, lab, radiology, surgery, anesthesia, exam and ... Wednesday, May 27 and Thursday, May 28 starting at 9:00am ... located at 1400 N. 25th Avenue, Melrose Park, IL 60160. ...
(Date:5/22/2015)... 2015 The world is at ... are intersecting to create new opportunities for leadership ... speaker at WesternU's 34th annual Commencement Exercises said ... Newsom, a former San Francisco mayor and likely ... the graduation ceremony for WesternU's colleges of Allied ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board ... system’s Chief Financial Officer (CFO), will be leaving the ... the company CFO since 2011. , The Board of ... health system as CFO. Wesley will oversee the health ... Board of Trustees conducts a formal search for a ...
(Date:5/22/2015)... Combination therapy, or polytherapy, will likely ... pulmonary disorder (COPD) as the dominant companies like ... well as Germany’s Boehringer Ingelheim compete with each ... market payers, clinicians and patients be disposed to ... new ones? , In spite of recently approved ...
(Date:5/22/2015)... 2015 Carnegie Science Center ... a new partnership to develop BodyTech, a dynamic, three-pronged ... initiative includes a new exhibit at the Science Center ... and a new traveling science show, Anatomy Adventure, which ... , Designed to explore a wide range of ...
Breaking Medicine News(10 mins):Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... American Cancer Society study of twelve types of cancer ... patients were significantly more likely to present with advanced ... study, which appears in the March issue of The ... to investigate insurance status and stage of diagnosis for ...
... es Salaam, Tanzania, WASHINGTON, Feb. 17 , 1:35 ... dear wife -- Mr.,President, welcome again to Amana Hospital. Well, ... for PEPFAR, the President,s,Emergency Plan for AIDS Relief., Through ... a,facility we just visited, and again, this clinic. In Dar ...
... Month, , , SUNDAY, Feb. 17 (HealthDay News) ... Americans about age-related macular degeneration (AMD), Prevent Blindness ... Month. , AMD -- a progressive disease that ... $570 million a year in direct costs for ...
... that a new wave of drug-resistant HIV is rising among among ... this trend will continue over the next few years, according to ... , At the same time, the evolution of drug-resistant HIV may ... men from becoming infected. , The model and ...
... The public health problem that needs to be addressed ... physicians who have come together to discuss the latest in ... the American Academy of Pain Medicine (AAPM), February 12-16 at ... decades, Americans, with the help of their physicians, have been ...
... people with depression , , SATURDAY, Feb. 16 (HealthDay News) -- ... syndrome (IBS) in adults, says a study by researchers at ... about 15 percent of the U.S. population. Some studies have ... some patients, but the frequency hadn,t been examined. , In ...
Cached Medicine News:Health News:Major study links insurance status to advanced stage in multiple cancers 2Health News:Remarks By President Bush and President Kikwete of Tanzania at Roundtable on Pepfar 2Health News:Don't Lose Sight of Vision Care, Group Urges 2Health News:Novel mathematical model predicts new wave of drug-resistant HIV infections in San Francisco 2Health News:Physicians focus on stopping pain epidemic 2Health News:Physicians focus on stopping pain epidemic 3Health News:Physicians focus on stopping pain epidemic 4Health News:Physicians focus on stopping pain epidemic 5Health News:Physicians focus on stopping pain epidemic 6Health News:Allergy Disorders Linked With Irritable Bowel Syndrome 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: